316 related articles for article (PubMed ID: 31607180)
1. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs.
Averell CM; Stanford RH; Laliberté F; Wu JW; Germain G; Duh MS
J Asthma; 2021 Jan; 58(1):102-111. PubMed ID: 31607180
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
[TBL] [Abstract][Full Text] [Related]
3. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
Bernstein D; Andersen L; Forth R; Jacques L; Yates L
J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
[TBL] [Abstract][Full Text] [Related]
4. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
[TBL] [Abstract][Full Text] [Related]
5. Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database.
Atsuta R; Takai J; Mukai I; Kobayashi A; Ishii T; Svedsater H
Pulm Ther; 2018 Dec; 4(2):135-147. PubMed ID: 32026395
[TBL] [Abstract][Full Text] [Related]
6. Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study.
Parimi M; Svedsater H; Ann Q; Gokhale M; Gray CM; Hinds D; Nixon M; Boxall N
Adv Ther; 2020 Jun; 37(6):2916-2931. PubMed ID: 32361850
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Adherence and Asthma Medication Ratio for a Once-Daily and Twice-Daily Inhaled Corticosteroid/Long-Acting β-Agonist for Asthma.
Stanford RH; Averell C; Parker ED; Blauer-Peterson C; Reinsch TK; Buikema AR
J Allergy Clin Immunol Pract; 2019; 7(5):1488-1496.e7. PubMed ID: 30639604
[TBL] [Abstract][Full Text] [Related]
8. Adherence and usage patterns of inhaled corticosteroids-long-acting beta-agonists by using inhaler-monitoring technology.
Stanford RH; Averell CM; Johnson PT; Buysman EK; Carlyle MH
Allergy Asthma Proc; 2020 Jul; 41(4):256-264. PubMed ID: 32605696
[No Abstract] [Full Text] [Related]
9. Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study.
Sicras-Mainar A; Gómez Rodríguez B; Traseira-Lugilde S; Fernández-Sánchez T; Velasco Garrido JL
BMJ Open; 2022 Apr; 12(4):e053964. PubMed ID: 35443946
[TBL] [Abstract][Full Text] [Related]
10. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
13. Vilanterol and fluticasone furoate for asthma.
Dwan K; Milan SJ; Bax L; Walters N; Powell C
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD010758. PubMed ID: 27582089
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
Adachi M; Goldfrad C; Jacques L; Nishimura Y
Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
16. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma-mixed treatment comparisons of clinical efficacy.
Svedsater H; Stynes G; Wex J; Frith L; Leather D; Castelnuovo E; Detry M; Berry S
Asthma Res Pract; 2016; 2():4. PubMed ID: 27965772
[TBL] [Abstract][Full Text] [Related]
17. Symptom control in patients with asthma using inhaled corticosteroids/long-acting β
Averell CM; Laliberté F; Germain G; Duh MS; Lima R; Mahendran M; Slade DJ
J Asthma; 2022 Sep; 59(9):1805-1818. PubMed ID: 34375568
[TBL] [Abstract][Full Text] [Related]
18. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy.
Hozawa S; Terada M; Haruta Y; Hozawa M
Pulm Pharmacol Ther; 2016 Apr; 37():15-23. PubMed ID: 26850307
[TBL] [Abstract][Full Text] [Related]
19. Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management.
Busse WW; Abbott CB; Germain G; Laliberté F; MacKnight SD; Jung Y; Duh MS; Averell CM
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2904-2913.e6. PubMed ID: 35752431
[TBL] [Abstract][Full Text] [Related]
20. An innovative corticosteroid/long-acting β
Usmani O; Roche N; Marshall J; Danagher H; Price D
Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
